No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CYTK Cytokinetics
- 65.340
- +0.540+0.83%
Close Apr 26 16:00 ET
- 63.600
- -1.740-2.66%
Post 19:56 ET
6.85BMarket Cap-11988P/E (TTM)
66.120High64.500Low738.06KVolume65.000Open64.800Pre Close48.25MTurnover0.71%Turnover RatioLossP/E (Static)104.77MShares110.25052wk High-17.72P/B6.80BFloat Cap25.98052wk Low--Dividend TTM104.08MShs Float110.250Historical High--Div YieldTTM2.50%Amplitude3.050Historical Low65.376Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Cytokinetics Appoints Sung H. Lee as New CFO
Express News | Cytokinetics - on April 23, Entered Employment Offer Letter With Sung H. Lee, Pursuant to Which, Lee Agreed to Serve as Executive Vice President, CFO
Cytokinetics(CYTK.US) Director Sells US$681.67K in Common Stock
$Cytokinetics(CYTK.US)$ Director HENDERSON JOHN T sold 10,562 shares of common stock on Apr 25, 2024 at an average price of $64.54 for a total value of $681.67K.Source: Announcement What is statement
Form 144 | Cytokinetics(CYTK.US) Director Proposes to Sell 681.63K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 25, $Cytokinetics(CYTK.US)$ Director JOHN T HENDERSON intends to sell 10,562 shares of its common stock on Apr 25, with a total market value of approximately $681.63K. JO
Express News | Cytokinetics to Announce First Quarter Results on May 8, 2024
Analysts' Top Healthcare Picks: Cytokinetics (CYTK), Ultragenyx Pharmaceutical (RARE)
Comments
Updated Complete & Utter M&A Guesses Purely for Entertainment Purposes:
$SPDR S&P Biotech ETF(XBI.US$
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x %$Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
$Merck & Co(MRK.US$ x $Immunovant(IMVT.US$
$Eli Lilly and Co(LLY.US$ x $Cytokinetics(CYTK.US$ (and soon)
$Regeneron Pharmaceuticals(REGN.US$ x $Apellis Pharmaceuticals(APLS.US$ (panache & brash)
$Gilead Sciences(GILD.US$ x %$Madrigal Pharmaceuticals(MDGL.US$ (liver king)
$Bristol-Myers Squibb(BMY.US$ x $Iovance Biotherapeutics(IOVA.US$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US$ x $Merus(MRUS.US$ (partner n...
2
CEO's belief in the company's potential to grow independently may have led to a 3% stock dip. Speculation around a Novartis takeover, and its withdrawal, could have swayed investor sentiment.
1
Sunday Update Mar 3
I'm going to try something new. I'm going to make a Sunday post so that it can be read before the market opens. I hope to still do my update before the market opens on Monday, I always want to see how futures move overnight.
This new thing I'm trying will be some random thoughts about the market. How to use some features on moomoo (a request by some) to do research and develop trading levels. To show this I will introduce some stocks iam in or will be starting positions in.
...
This new thing I'm trying will be some random thoughts about the market. How to use some features on moomoo (a request by some) to do research and develop trading levels. To show this I will introduce some stocks iam in or will be starting positions in.
...
+36
55
18
Truist analyst Srikripa Devarakonda views the recent weakness in Cytokinetics' stock as a buying opportunity and maintains a buy rating and $86 price target on the stock. Devarakonda continues to see Cytokinetics as a potential M&A target.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg